# A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

> **NCT00001669** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 15 (—)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** rhIGF-1 (CEP-151)

## Key facts

- **NCT ID:** NCT00001669
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** 2000-04
- **Target enrollment:** 15 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001669, "A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00001669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*